Physician profile
Chiniya Thapa
NPI 1295049146
$2,361.28
in general payments reported to CMS, 2019-2025
28 companies · $18.81 in 2025
The $18.81 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $526 · 2021: $161 · 2023: $414 · 2024: $755 · 2025: $18.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.76 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $336.47 | 2021-2024 | Ubrelvy, Vraylar |
| Lilly USA, LLC | $308.11 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $215.50 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $215.07 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.79 | 2019-2024 | Xifaxan |
| Pfizer INC. | $120.02 | 2019-2025 | |
| Covidien Lp | $113.26 | 2019 | |
| Amarin Pharma, INC. | $111.43 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $108.22 | 2019-2024 | Airsupra |
| Amgen INC. | $81.31 | 2019-2024 | Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $77.29 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $76.54 | 2020-2024 | Eliquis |
| Nestle Healthcare Nutrition INC. | $58.59 | 2023 | |
| Janssen Pharmaceuticals, INC | $53.58 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $50.83 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $48.54 | 2019-2020 | |
| Medtronic, INC. | $29.16 | 2024 | Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $27.71 | 2019-2020 | |
| Corcept Therapeutics | $25.69 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $23.48 | 2023 | |
| Lundbeck LLC | $23.47 | 2024 | Rexulti |
| Esperion Therapeutics, INC. | $20.53 | 2024 | Nexletol |
| Astellas Pharma US INC | $20.06 | 2020 | |
| Sumitomo Pharma America, INC. | $19.91 | 2023 | Gemtesa |
| Exact Sciences Corporation | $18.87 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $18.11 | 2020 | |
| Sanofi Pasteur INC. | $12.94 | 2020 | |
| Collegium Pharmaceutical, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chiniya Thapa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.